According to the narrow specific criteria indicated by Cook, AVI would not work.
Cook mentioned they would be interested in a company with a drug that is near term (e.g. through, or almost through phase III) and with a bit of a black hole in terms of any trailing opportunities (e.g. maybe no further pipeline drugs beyond Phase I or early Phase II).
